07:00 , Mar 19, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Dedicator of cytokinesis 5 (DOCK5)

Musculoskeletal disease INDICATION: Osteoporosis In vitro and mouse studies suggest a DOCK5 inhibitor could help treat osteoporosis. DOCK5 has been implicated in osteoclast activity and bone resorption. In vitro, C21 , a small molecule inhibitor...
07:00 , May 2, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer Dedicator of cytokinesis 1 (DOCK1) Patient sample and mouse studies suggest inhibiting DOCK1 could help prevent breast cancer metastasis....
07:00 , May 10, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Autoimmune disease Dedicator of cytokinesis 2 (DOCK2) In vitro and mouse studies identified a small molecule DOCK2 inhibitor that could help treat autoimmune disease....
07:00 , May 15, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Dedicator of cytokinesis 7 (Dock7); neuregulin 1 (NRG1) A study in cell culture suggests that antagonizing Dock7 could help treat...